Abstract
Vaccines have long been considered as a crucial control measure for infectious diseases. The initial development of effective antigen (subunit)-based vaccines against pathogens was of limited efficiency. Only a handful of candidate antigens were studied at a time, and relatively few became components of successful vaccines. Thus the traditional vaccine development process from laboratory bench (candidate discovery and testing) to bedside (licensing and usasge) was slow, and particularly unsuitable for a rapid response to emergent epidemics or pandemics. This chapter provides a detailed description, with examples, of the high-throughput approach known as reverse vaccinology, and related methods, aimed at rapidly identifying antigens suitable for use in subunit vaccines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
